Key Takeaways
- Regencell Bioscience Holdings shares took off when a 38-to-1 stock split went into effect.
- The biotech that does research to treat children’s diseases using traditional Chinese medicine announced the forward stock split June 2.
- Regencell said the split was designed to “enhance liquidity” and “make the shares more accessible to investors.”
It’s been quite a good month for investors in Regencell Bioscience Holdings (RGC).
Shares of the Hong Kong-firm that focuses on the use of traditional Chinese medicine to treat Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD) in children more than quadrupled on the first day a huge 38-to-1 stock split took effect.
The company announced the split June 2, and that the stock would be distributed June 13.
Regencell said the move was intended to “enhance liquidity in the market for the Company’s ordinary shares and make the shares more accessible to investors.”
TradingView
:max_bytes(150000):strip_icc()/GettyImages-2207639894-ec10a2671ceb4a318d7f4612f06570a1.jpg?ssl=1&description=Regencell+Bioscience+Stock+Skyrockets+as+38-to-1+Split+Takes+Effect){kind=link}